|
Abdominal Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, even when serum amylase and lipase levels are normal, AP should be kept in mind when making a differential diagnosis of patients with diabetes mellitus who present with abdominal pain and take dipeptidyl peptidase-4 (DPP-4) inhibitors.
|
29086719 |
2017 |
|
Acquired Hypogammaglobulinemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Soluble CD26 and CD30 levels in patients with common variable immunodeficiency.
|
23654079 |
2013 |
|
Acromegaly
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oral antidiabetic drugs were used in 36.5% of patients with acromegaly and 40% with Cushing´s disease, with a predominance of biguanides and dipeptidyl peptidase-4 inhibitors.
|
30332686 |
2020 |
|
Acute Coronary Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear.
|
29301579 |
2018 |
|
Acute Coronary Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
The cardiovascular (CV) outcomes of vildagliptin - a dipeptidyl peptidase-4 inhibitor - in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke are unclear.
|
31115964 |
2020 |
|
Acute Coronary Syndrome
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In contrast, cardiovascular outcome trials examining the safety of the shorter-acting GLP-1R agonist lixisenatide (ELIXA trial [Evaluation of Lixisenatide in Acute Coronary Syndrom]) and the DPP-4 inhibitors saxagliptin (SAVOR-TIMI 53 trial [Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53]), alogliptin (EXAMINE trial [Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome]), and sitagliptin (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin]) found that these agents neither increased nor decreased cardiovascular events.
|
28847797 |
2017 |
|
Acute exacerbation of chronic obstructive airways disease
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
ROC analysis indicated that serum DPPIV concentration in all groups showed a good diagnostic accuracy, especially in stable COPD and AECOPD groups.
|
26992252 |
2016 |
|
Acute leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we analyzed the CD26 antigen cell membrane expression by flow cytometry and the DPPIV activity in plasma of patients of acute leukemia.
|
19469710 |
2009 |
|
Acute lymphocytic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CD25 (IL-2RA) and CD26 (DPPIV) were expressed on LSCs in Ph<sup>+</sup> ALL exhibiting BCR/ABL1<sub>p210</sub>, whereas in Ph<sup>+</sup> ALL with BCR/ABL1<sub>p190</sub>, LSCs variably expressed CD25 but did not express CD26.
|
29772458 |
2018 |
|
Acute lymphocytic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Although CD26 expression on immune cells were not leukemia-dependent the analysis of the correlation between CD26 expression and the DPPIV plasma activity were statistically significant (p < 0.01) in acute lymphoid leukemia (B-ALL and T-ALL).
|
19469710 |
2009 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
DPP-4 inhibitor therapy improved long-term survival in diabetic patients after first AMI, regardless of gender.
|
28697774 |
2017 |
|
Acute on chronic pancreatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To determine the association between the use of incretin agents (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) for the treatment of type 2 diabetes mellitus (T2DM) and the risk of any, acute and chronic pancreatitis.
|
27883260 |
2017 |
|
Acute pancreatitis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
There is a marginally higher risk of acute pancreatitis with DPP-4 inhibitors.
|
29310393 |
2017 |
|
Acute pancreatitis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).
|
27630212 |
2017 |
|
Acute pancreatitis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The second focuses on dipeptidyl peptidase-4 inhibitors and acute pancreatitis, using a nested case-control design.
|
31436848 |
2019 |
|
Acute pancreatitis
|
0.090 |
Biomarker
|
disease |
BEFREE |
After controlling for potential confounders, the risk was not significantly increased or decreased for initiators of DPP4 inhibitors compared to sulfonylureas (hazard ratio (HR) [95% confidence interval (CI)] for acute kidney injury: 0.81 [0.56-1.18]; HR for respiratory tract infections: 0.93 [0.84-1.04]; HR for acute pancreatitis 1.03 [0.42-2.52], metformin (HR for respiratory tract infection 0.91 [0.65-1.27]), thiazolidinediones (HR for acute kidney injury: 1.12 [0.60-2.10]; HR for respiratory tract infections: 1.02 [0.86-1.21]; HR for acute pancreatitis: 1.21 [0.25-5.72]), or insulin (HR for acute kidney injury: 1.40 [0.77-2.55]; HR for respiratory tract infections: 0.74 [0.60-0.92]; HR for acute pancreatitis: 1.01 [0.24-4.19]).
|
30310100 |
2018 |
|
Acute pancreatitis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
DPP-4 inhibitors were associated with increased risk for acute pancreatitis (Peto odds ratio 1.72; 95% CI 1.18-2.53), with an NNH of 1066 patients, but the optimal sample size for this outcome was not reached.
|
29335646 |
2018 |
|
Acute pancreatitis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Information on the risk of acute pancreatitis in patients receiving dipeptidyl-peptidase IV inhibitors (DPP-4i) is limited and controversial.
|
29850606 |
2018 |
|
Acute pancreatitis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
|
29618573 |
2018 |
|
Acute pancreatitis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
All individual DPP-4 inhibitors displayed a non-significant trend towards an increased risk of acute pancreatitis, which was significant in the meta-analysis [1.75 (1.14-2.70); P = 0.01].
|
31750601 |
2020 |
|
Acute pancreatitis
|
0.090 |
Biomarker
|
disease |
BEFREE |
DPP4 Inhibitor Attenuates Severe Acute Pancreatitis-Associated Intestinal Inflammation via Nrf2 Signaling.
|
31827684 |
2019 |
|
Acute respiratory infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus.
|
30626685 |
2019 |
|
Acute type A viral hepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunoprecipitation confirmed that DPP4 is displayed on the surface of eHAV produced in cell culture or present in sera from humans with acute hepatitis A.
|
28490497 |
2017 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade.
|
12675245 |
2003 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade.
|
12634639 |
2003 |